Jam today? Turning pharma's costs into assets
This article was originally published in Scrip
I recently came across details of a new economic theory being developed with environmental policy in mind that may have lessons for pharma. In a nutshell, the project – led by the FWF Austrian Science Fund, the central funding organization for basic research in Austria – is aimed at finding ways of rewarding people today for investing for the benefit of future generations.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.